Clareo Health | CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer
Locally advanced pancreatic cancer, defined by the DPCG consensus criteria as: arterial involvement \>90 degrees or venous involvement \>270 degrees.
At least RECIST stable disease after a minimum two months of chemotherapy according to current clinical practice\*
Capable of providing written and oral informed consent
Candidate for RNT, judged by a multidisciplinary tumor board
WHO 0-2
You may not be if
Eligibility for resection
Participation in other trials focussing on different ablative treatment modalities such as radiofrequency ablation or irreversible electroporation for LAPC
Known hypersensitivity to silicon or phosphor
Bleeding disorders which cannot be corrected with medication
Inability/unwillingness to interrupt anticoagulation therapy
Pregnancy
Metastatic pancreatic cancer
Epilepsy episode(s) in the past six months
Longest tumor diameter \>70 mm or total target tumor volume \>110 ml
Presence of multiple collateral vessels surrounding or adjacent to the target tumor on radiologic imagining, prohibiting safe injection of the OncosilTM device
Presence (or significant risk) of varices near the target tumor on radiologic imaging
Recent clinically significant pancreatitis
Previous administration of radiotherapy to the pancreas
